^
    Back
    Association details:
    Biomarker:TNFRSF4 expression
    Cancer:Head and Neck Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-SITC 2020
    Title:

    Activation of memory/effector T cells and association between prognosis and OX40-positive T cells in advanced head and neck cancer patients treated with anti-programmed death-1 antibody.

    Published date:
    02/06/2020
    Excerpt:
    The expression level of OX40 on T cells was correlated with efficacy of nivolumab therapy in HNC patients.